France removes state funding for dementia drugs

BMJ

17 January 2020 - The first country in Europe to act on concerns over limited effectiveness.

In May 2018 the French minister of health announced the delisting of drug treatments for dementia; payments for memantine and the acetylcholinesterase inhibitors donepezil, rivastigmine, and galantamine would no longer be reimbursed by the state. 

The decision followed a long campaign by the French therapeutics journal Prescrire, which subsequently declared, “The days are over when support for patients and their struggling caregivers was based on drugs raising false hopes.”

Read BMJ Editorial

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Market access , France